Display Settings:


Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Acta Clin Belg. 1991;46(3):150-8.

Benefit of intravenous essential amino-acids in catabolic patients on chronic maintenance hemodialysis.

Author information

  • 1Nephrology Department, University Hospital, Ghent, Belgium.


The effect on the clinical status of catabolic hemodialysis patients of I.V. essential amino-acids administered over 3 months at the end of each dialysis is assessed in an open clinical follow-up study of 10 patients; these patients showed a progressive deterioration of general condition and a progressive weight loss in the period before the start of the treatment. The study was undertaken in a hospital dialysis unit, with as main outcome measures body weight, hematocrit, a scoring index of general condition and degree of edema. In patients showing a progressive and consistent loss of body weight in the months preceding the study, after the first treatment month, body weight started to rise, increasing after 3 months from 56.2 +/- 2.3 to 58.6 +/- 2.4 kg (p less than 0.01). The hematocrit raised from 22.4 +/- 1.6% up to 26.5 +/- 1.9% (p less than 0.02). Over this period, only 2 liters of packed cells were administered, in contrast to an overall need of 13 liters in the preceding 6 months. Peripheral and/or pulmonary edema disappeared. A scoring index, of general condition, increased from 5.1 +/- 1.5 before the start of the study to 11.7 +/- 0.8 after 3 months (p less than 0.01). It is concluded that the parenteral administration of amino-acids in catabolic patients on chronic hemodialysis has a beneficial effect on general condition, and the balance of body fluid and body mass.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk